Application of indinavir and/or derivatives thereof in preparation of antituberculous drugs
The invention provides application of indinavir and/or derivatives thereof in preparation of antituberculosis drugs, and relates to the technical field of medicines. Indinavir is an anti-reverse transcriptase inhibitor and can be combined with an HIV protease catalytic site to inhibit division of a virus polyprotein precursor into a mature functional protein required by virus replication. Indinavir can be used in cooperation with other anti-retroviral agents to treat HIV infection; the application finds that the indinavir has an effect of inhibiting intracellular survival of mycobacterium tuberculosis at a macrophage level, that is, the indinavir has a potential as an antituberculosis drug, and has an important application value in clinical treatment of HIV combined MTB infection..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Europäisches Patentamt - (2024) vom: 30. Jan. Zur Gesamtaufnahme - year:2024 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
GUO QINGLONG [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Sonstige Themen: |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-30, Last update posted on www.tib.eu: 2024-04-08, Last updated: 2024-04-15 |
---|
Patentnummer: |
CN117462551 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA002709074 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA002709074 | ||
003 | DE-627 | ||
005 | 20240415111101.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240329s2024 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA002709074 | ||
035 | |a (EPA)CN117462551 | ||
035 | |a (EPA)89633269 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a GUO QINGLONG |e verfasserin |4 aut | |
245 | 1 | 0 | |a Application of indinavir and/or derivatives thereof in preparation of antituberculous drugs |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-30, Last update posted on www.tib.eu: 2024-04-08, Last updated: 2024-04-15 | ||
520 | |a The invention provides application of indinavir and/or derivatives thereof in preparation of antituberculosis drugs, and relates to the technical field of medicines. Indinavir is an anti-reverse transcriptase inhibitor and can be combined with an HIV protease catalytic site to inhibit division of a virus polyprotein precursor into a mature functional protein required by virus replication. Indinavir can be used in cooperation with other anti-retroviral agents to treat HIV infection; the application finds that the indinavir has an effect of inhibiting intracellular survival of mycobacterium tuberculosis at a macrophage level, that is, the indinavir has a potential as an antituberculosis drug, and has an important application value in clinical treatment of HIV combined MTB infection. | ||
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a BI JING |e verfasserin |4 aut | |
700 | 0 | |a ZHANG GUOLIANG |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 30. Jan. |
773 | 1 | 8 | |g year:2024 |g day:30 |g month:01 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89633269/publication/CN117462551A1?q=CN117462551 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
951 | |a AR | ||
952 | |j 2024 |b 30 |c 01 |